Transgene IL-6 Enhances DC-Stimulated CTL Responses by Counteracting CD4+25+Foxp3+ Regulatory T Cell Suppression via IL-6-Induced Foxp3 Downregulation

International Journal of Molecular Sciences

Volumn 15, Issue 4, 2014, Pages 5508-5521

  Bhanumathy, Kalpana Kalyanasundaram ^a,b   Zhang, Bei ^a,b   Ahmed, Khawaja Ashfaque ^a,b   Qureshi, Mabood ^b   Xie, Yufeng ^c   Tao, Min ^c   Tan, Xin ^d   Xiang, Jim ^a,b  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Antitumor immunity; Cytotoxic T lymphocytes (CTLs); Dendritic cells (DCs); Forkhead box P3 (Foxp3); Interleukin 6 (IL 6)

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; CANCER VACCINE; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR ALPHA; OVALBUMIN; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MOLECULAR CLONING; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; PROCEDURES; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE; VACCINATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD4; CANCER VACCINES; CELL LINE, TUMOR; CLONING, MOLECULAR; DENDRITIC CELLS; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSFECTION; VACCINATION; VACCINES, SYNTHETIC;

EID: 84897428851     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15045508     Document Type: Article

References (54)

1. + T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cell. Mol. Immunol. 2007, 4, 277-285.
2. Klebanoff, C.A.; Acquavella, N.; Yu, Z.; Restifo, N.P. Therapeutic cancer vaccines: Are we there yet? Immunol. Rev. 2011, 239, 27-44.
3. Palucka, K.; Ueno, H.; Banchereau, J. Recent developments in cancer vaccines. J. Immunol. 2011, 186, 1325-1331.
4. Galluzzi, L.; Senovilla, L.; Vacchelli, E.; Eggermont, A.; Fridman, W.H.; Galon, J.; Sautès-Fridman, C.; Tartour, E.; Zitvogel, L.; Kroemer, G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012, 1, 1111-1134.
5. Melief, C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29, 372-383.
6. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10, 909-915.
7. Schluns, K.S.; Lefrancois, L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 2003, 3, 269-279.
8. Akiyama, Y.; Watanabe, M.; Maruyama, K.; Ruscetti, F.W.; Wiltrout, R.H.; Yamaguchi, K. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther. 2000, 7, 2113-2121.
9. Ojima, T.; Iwahashi, M.; Nakamura, M.; Matsuda, K.; Naka, T.; Nakamori, M.; Ueda, K.; Ishida, K.; Yamaue, H. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int. J. Oncol. 2006, 28, 947-953.
10. Tourkova, I.L.; Yurkovetsky, Z.R.; Gambotto, A.; Makarenkova, V.P.; Perez, L.; Balkir, L.; Robbins, P.D.; Shurin, M.R.; Shurin, G.V. Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. J. Leukoc. Biol. 2002, 72, 1037-1045.
11. Zhang, W.; Chen, Z.; Li, F.; Kamencic, H.; Juurlink, B.; Gordon, J.R.; Xiang, J. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003, 108, 177-188.
12. Pasare, C.; Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299, 1033-1036.
13. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441, 235-238.
14. Schuler, G.; Steinman, R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 1997, 186, 1183-1187.
15. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
16. Sallusto, F.; Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 1994, 17, 1109-1118.
17. Palucka, K.; Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39, 38-48.
18. Strioga, M.M.; Felzmann, T.; Powell, D.J., Jr.; Ostapenko, V.; Dobrovolskiene, N.T.; Matuskova, M.; Michalek, J.; Schijns, V.E. Therapeutic dendritic cell-based cancer vaccines: The state of the art. Crit. Rev. Immunol. 2013, 33, 489-547.
19. Huang, C.; Ramakrishnan, R.; Trkulja, M.; Ren, X.; Gabrilovich, D.I. Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol. Immunother. 2012, 61, 573-579.
20. Vogt, A.; Sievers, E.; Lukacs-Kornek, V.; Decker, G.; Raskopf, E.; Meumann, N.; Büning, H.; Sauerbruch, T.; Strassburg, C.P.; Schmidt-Wolf, I.G. et al. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int. 2013, doi:10.1111/liv.12284.
21. Qu, Y.; Taylor, J.L.; Bose, A.; Storkus, W.J. Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther. 2011, 18, 663-673.
22. Taga, T.; Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15, 797-819.
23. Naugler, W.E.; Karin, M. The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008, 14, 109-119.
24. Harrington, L.E.; Hatton, R.D.; Mangan, P.R.; Turner, H.; Murphy, T.L.; Murphy, K.M.; Weaver, C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6, 1123-1132.
25. Weaver, C.T.; Hatton, R.D.; Mangan, P.R.; Harrington, L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25, 821-852.
26. Ankathatti Munegowda, M.; Xu, S.; Freywald, A.; Xiang, J. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene. Mol. Immunol. 2012, 51, 143-149.
27. Liu, Y.; Zhang, X.; Zhang, W.; Chen, Z.; Chan, T.; Ali, K.; Jia, Z.; Xiang, J. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 2002, 9, 202-208.
28. Hirschowitz, E.A.; Weaver, J.D.; Hidalgo, G.E.; Doherty, D.E. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther. 2000, 7, 1112-1120.
29. Rouard, H.; Leon, A.; Klonjkowski, B.; Marquet, J.; Tenneze, L.; Plonquet, A.; Agrawal, S.G.; Abastado, J.P.; Eloit, M.; Farcet, J.P. et al. Adenoviral transduction of human "clinical grade" immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J. Immunol. Methods 2000, 241, 69-81.
30. Morelli, A.E.; Larregina, A.T.; Ganster, R.W.; Zahorchak, A.F.; Plowey, J.M.; Takayama, T.; Logar, A.J.; Robbins, P.D.; Falo, L.D.; Thomson, A.W. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway. J. Virol. 2000, 74, 9617-9628.
31. Philpott, N.J.; Nociari, M.; Elkon, K.B.; Falck-Pedersen, E. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc. Natl. Acad. Sci. USA 2004, 101, 6200-6205.
32. Bluestone, J.A.; Abbas, A.K. Natural vs. adaptive regulatory T cells. Nat. Rev. Immunol. 2003, 3, 253-257.
33. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299, 1057-1061.
34. + regulatory T cells. Nat. Immunol. 2003, 4, 330-336.
35. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. USA 2005, 102, 6449-6454.
36. Lipscomb, M.W.; Taylor, J.L.; Goldbach, C.J.; Watkins, S.C.; Wesa, A.K.; Storkus, W.J. DC expressing transgene Foxp3 are regulatory APC. Eur. J. Immunol. 2010, 40, 480-493.
37. Liyanage, U.K.; Moore, T.T.; Joo, H.G.; Tanaka, Y.; Herrmann, V.; Doherty, G.; Drebin, J.A.; Strasberg, S.M.; Eberlein, T.J.; Goedegebuure, P.S. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169, 2756-2761.
38. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
39. Levings, M.K.; Sangregorio, R.; Roncarolo, M.G. Human CD25(+)CD4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 2001, 193, 1295-1302.
40. Martin, B.; Banz, A.; Bienvenu, B.; Cordier, C.; Dautigny, N.; Bécourt, C.; Lucas, B. Suppression of CD4+ T lymphocyte effector functions by CD4+CD25+ cells in vivo. J. Immunol. 2004, 172, 3391-3398.
41. + helper T cell responses in cancer patients. Blood 2005, 106, 1008-1011.
42. + T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 2004, 172, 4676-4680.
43. Pardoll, D.M. Cancer vaccines. Nat. Med. 1998, 4, 525-531.
44. + T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. J. Leukoc. Biol. 2012, 92, 289-300.
45. Moulin, V.; Morgan, M.E.; Eleveld-Trancikova, D.; Haanen, J.B.; Wielders, E.; Looman, M.W.; Janssen, R.A.; Figdor, C.G.; Jansen, B.J.; Adema, G.J. Targeting dendritic cells with antigen via dendritic cell-associated promoters. Cancer Gene Ther. 2012, 19, 303-311.
46. + T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 2010, 5, e11144.
47. Sato, M.; Chamoto, K.; Nishimura, T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int. Immunol. 2003, 15, 837-843.
48. Ben-Sasson, S.Z.; Makedonski, K.; Hu-Li, J.; Paul, W.E. Survival and cytokine polarization of naive CD4(+) T cells in vitro is largely dependent on exogenous cytokines. Eur. J. Immunol. 2000, 30, 1308-1317.
49. Curnow, S.J.; Scheel-Toellner, D.; Jenkinson, W.; Raza, K.; Durrani, O.M.; Faint, J.M.; Rauz, S.; Wloka, K.; Pilling, D.; Rose-John, S. et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J. Immunol. 2004, 173, 5290-5297.
50. Teague, T.K.; Schaefer, B.C.; Hildeman, D.; Bender, J.; Mitchell, T.; Kappler, J.W.; Marrack, P. Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. J. Exp. Med. 2000, 191, 915-926.
51. + T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J. Immunol. 2006, 177, 2976-2984.
52. Chan, T.; Sami, A.; El-Gayed, A.; Guo, X.; Xiang, J. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther. 2006, 13, 1391-1402.
53. Chen, Y.; Xie, Y.; Chan, T.; Sami, A.; Ahmed, S.; Liu, Q.; Xiang, J. Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice. Cancer Gene Ther. 2011, 18, 489-499.
54. + regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyteYewdall-mediated immunity against B16 melanoma. Biochem. Biophys. Res. Commun. 2013, 438, 152-155.